An analysis of data on the use of radiation therapy in a large clinical trial of patients with HR+, HER2- breast cancer who had one to three involved lymph nodes and a 21-gene recurrence score of 25 or less found that rates of locoregional recurrence of the disease were low regardless of whether a patient had received regional node irradiation. The results suggest that a randomized clinical trial is required to answer the question of whether these favorable-risk patients can safely skip RNI.
Researchers at NCI have completed a comprehensive analysis of cancer statistics for different age groups in the United States and found that from 2010 through 2019, the incidence of 14 cancer types increased among people under age 50.
